Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Phathom Pharmaceuticals's ROE % for the quarter that ended in Jun. 2026 was 0.00%. Phathom Pharmaceuticals's PB Ratio for the quarter that ended in Jun. 2026 was N/A.
Phathom Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2026 was N/A.
Phathom Pharmaceuticals ROE % Adjusted to Book Value Related Terms
Phathom Pharmaceuticals ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Phathom Pharmaceuticals's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Phathom Pharmaceuticals ROE % Adjusted to Book Value Chart
PHAT vs GERN, KURA, ODTX: ROE % Adjusted to Book Value Comparison
For the Biotechnology subindustry, Phathom Pharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Phathom Pharmaceuticals ROE % Adjusted to Book Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Phathom Pharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Phathom Pharmaceuticals's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of 0.00% mean?
Phathom Pharmaceuticals (PHAT) has a ROE % Adjusted to Book Value of 0.00% as of Jun. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Phathom Pharmaceuticals and its competitors.
Is Phathom Pharmaceuticals' ROE % Adjusted to Book Value too high?
Phathom Pharmaceuticals' current ROE % Adjusted to Book Value is 0.00%. Overall, Phathom Pharmaceuticals has a GF Score™ of 38/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Phathom Pharmaceuticals' ROE % Adjusted to Book Value compare to GERN and KURA?
Phathom Pharmaceuticals' ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Phathom Pharmaceuticals and its competitors. Phathom Pharmaceuticals's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Phathom Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Phathom Pharmaceuticals (PHAT) is currently considered Possible Value Trap. The stock's GF Value™ is $24.86, compared to a current price of $9.58 — trading 61.5% below its estimated fair value. The current ROE % Adjusted to Book Value is 0.00%. Phathom Pharmaceuticals' overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Phathom Pharmaceuticals (PHAT), the current ROE % Adjusted to Book Value is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Phathom Pharmaceuticals (PHAT) Overvalued in 2026?
Based on GuruFocus' analysis, Phathom Pharmaceuticals stock appears to be undervalued.
The current stock price of $9.58 is trading 61.5% below its estimated GF Value™ of $24.86.
GuruFocus considers Phathom Pharmaceuticals to be Possible Value Trap.
Key valuation signals for PHAT:
ROE % Adjusted to Book Value: 0.00%
GF Value™: $24.86 vs. price of $9.58 (61.5% below fair value)
No single metric tells the full story. See the PHAT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
38GF Score
Get the complete analysis for PHAT
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHAT has been successfully added to your 
